SciSparc Ltd.

Stage 4 · Declining · week 10

As of Oct 22, 2026, SciSparc is in Stage 4, the downtrend phase, now in week 10 (since Aug 18, 2026). It closed at $1.20, 96.7% below its 52-week high and below its 200-day average, which is falling.

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. More about the company

$1.20

-11.00% today

$697,167 · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is SPRC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 49w

S4 38w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 13w → S1 9w → S4 49w → S1 9w → S2 3w → S3 2w → S4 12w → S1 7w → S4 38w → S1 10w → S4 3w → S1 2w → S4 9w current

Total tracked: 166 weeks across 13 stage runs.

SPRC among Biotechnology537th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…537	SPRCSciSparc Ltd.	Stage 4 · wk 10	4	−76.0%

vs 52W High

-96.7%

$1.20 lo$36.18 hi

96.7% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 10

1w13w26w

Week 10, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-79.8%

200 DMA: $5.93 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.58x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-76.0%

-77.5%

-81.8%

YTD

-90.5%

-96.9%

Scan Membership

Breakout Watch

Latest: 2025-02-28

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 10 · Vol 0.58x

2026-10-21S4

Wk 10 · Vol 0.41x

2026-10-20S4

Wk 9 · Vol 0.13x

2026-10-19S4

Wk 9 · Vol 0.29x

2026-10-16S4

Wk 9 · Vol 0.52x

2026-10-15S4

Wk 9 · Vol 787.91x

2026-10-14S4

Wk 9 · Vol 0.28x

2026-10-13S4

Wk 8 · Vol 0.50x

2026-10-12S4

Wk 8 · Vol 0.23x

2026-10-09S4

Wk 8 · Vol 0.08x

2026-10-08S4

Wk 8 · Vol 0.03x

2026-10-07S4

Wk 8 · Vol 0.19x

Moving averages & range

50 DMA

$4.86

200 DMA

$5.93

52W High

$36.18

52W Low

$1.20

5D Low

$1.20

Resistance levels (recent highs)

20d High

$5.21

60d High

$8.70

120d High

$11.54

250d High

$36.18

Next resistance

+334.2%

to 20d High

P/E (TTM)

0.0

Forward —

ROE

-164.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.2

SciSparc: quick answers

What stage is SciSparc in?

As of Oct 22, 2026, SciSparc (SPRC) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 18, 2026 and is in week 10. What the four stages mean

Is SciSparc in an uptrend?

No. SciSparc is in a Stage 4 downtrend. It trades 79.8% below its 200-day average, which is falling.

How far is SciSparc from its 52-week high?

SciSparc closed at $1.20 on Oct 22, 2026, 96.7% below its 52-week high of $36.18. Its 52-week low is $1.20.

How has SciSparc performed over the past year?

As of Oct 22, 2026, SciSparc is down 96.9% over the past year and down 90.5% so far in 2026.

Which sector and industry is SciSparc in?

SciSparc is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.